The development of cancer occurs through malignant transformation – a stepwise process in which normal cells acquire genetic alterations, leading to their uncontrolled cell division and escape from immune cell recognition. Therapeutic approaches aim at reverting this process by inhibiting tumor cell proliferation and re-establishing recognition and clearance of malignant cells by the immune system. The Feucht and Leibold labs work at the interface of cancer biology and tumor immune cell interactions. Through insights into cancer cell intrinsic immune surveillance and escape mechanisms the labs aim to identify novel and personalised treatment strategies involving Chimeric Antigen Receptor (CAR) T and NK cells for patients with late stage malignancies.